Compare UHT & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHT | ZVRA |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.9M | 499.9M |
| IPO Year | N/A | 2015 |
| Metric | UHT | ZVRA |
|---|---|---|
| Price | $42.32 | $8.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.71 |
| AVG Volume (30 Days) | 105.3K | ★ 1.2M |
| Earning Date | 10-27-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | 0.54 |
| Revenue | ★ $100,898,000.00 | $84,388,000.00 |
| Revenue This Year | $0.71 | $333.25 |
| Revenue Next Year | $2.00 | $43.70 |
| P/E Ratio | $32.56 | ★ $15.50 |
| Revenue Growth | 1.00 | ★ 244.60 |
| 52 Week Low | $34.56 | $6.19 |
| 52 Week High | $43.00 | $13.16 |
| Indicator | UHT | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 69.00 | 38.00 |
| Support Level | $39.44 | $8.24 |
| Resistance Level | $43.00 | $9.03 |
| Average True Range (ATR) | 0.88 | 0.35 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 83.10 | 14.84 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.